The National Institute on Aging-Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials.
Alzheimer's disease
Amyloid
Biomarkers
Clinical trials
Disease modification
NIA-AA Framework
Neurodegeneration
Tau
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
20
02
2018
revised:
27
04
2018
accepted:
03
05
2018
pubmed:
25
6
2018
medline:
19
7
2019
entrez:
25
6
2018
Statut:
ppublish
Résumé
The National Institute on Aging-Alzheimer's Association Research Framework on Alzheimer's disease (AD) represents an important advance in the biological characterization of the AD spectrum. The National Institute on Aging-Alzheimer's Association Framework is considered as it applies to clinical trials. Using the combination of amyloid (A), tau (T), and neurodegeneration (N) biomarkers, the Framework provides a means of defining the state of patients with regard to Alzheimer pathologic change. The Framework is relevant to clinical trials of disease-modifying agents, allowing participants to be characterized biologically at baseline. The ATN Framework can also inform trial outcomes. The preclinical phase of the disease after amyloid deposition is defined by A+T-N-, and the transition to prodromal disease and dementia is characterized by the addition of T and N. Most symptomatic patients in clinical trials are in the class of A+T+N- and A+T+N+. The National Institute on Aging-Alzheimer's Association Framework on AD represents progress in providing biomarker profiles of participants in the AD spectrum that can be used to help design clinical trials.
Identifiants
pubmed: 29936146
pii: S1552-5260(18)30160-2
doi: 10.1016/j.jalz.2018.05.006
pmc: PMC6417790
mid: NIHMS1502861
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
172-178Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM109025
Pays : United States
Informations de copyright
Copyright © 2018 The Author. Published by Elsevier Inc. All rights reserved.
Références
Neurology. 2005 May 10;64(9):1563-72
pubmed: 15883317
Neurobiol Aging. 2017 Nov;59:210-219
pubmed: 28890300
J Alzheimers Dis. 2013;35(4):799-811
pubmed: 23481687
JAMA Neurol. 2015 Jun;72(6):656-65
pubmed: 25867677
Ann Neurol. 2018 Jan;83(1):74-83
pubmed: 29244218
Brain. 2017 Mar 1;140(3):748-763
pubmed: 28077397
Ann Neurol. 2016 Jan;79(1):110-9
pubmed: 26505746
Arch Neurol. 2005 May;62(5):721-8
pubmed: 15883258
Ann Neurol. 2017 Apr;81(4):549-559
pubmed: 28224671
Neurology. 2011 Sep 27;77(13):1263-71
pubmed: 21917762
Sci Transl Med. 2016 May 11;8(338):338ra66
pubmed: 27169802
Mol Psychiatry. 2017 Feb;22(2):306-311
pubmed: 27021814
Transl Neurodegener. 2017 Sep 26;6:25
pubmed: 29021896
Alzheimers Dement. 2018 Apr;14(4):535-562
pubmed: 29653606
Brain. 2016 Nov 1;139(11):2983-2993
pubmed: 27694152
J Alzheimers Dis. 2013;33(4):929-39
pubmed: 23047371
Alzheimers Dement. 2018 Apr;14(4):532-534
pubmed: 29653605
J Alzheimers Dis. 2015;48(1):175-87
pubmed: 26401938
J Alzheimers Dis. 2018;64(s1):S3-S22
pubmed: 29562511
Neurobiol Aging. 2012 Jul;33(7):1253-7
pubmed: 21489655
Dement Geriatr Cogn Disord. 2009;27(5):474-80
pubmed: 19439965
Alzheimers Dement. 2018 Apr;14(4):576-578
pubmed: 29653608
Neurology. 2016 Jul 26;87(4):375-83
pubmed: 27358341
Neurobiol Aging. 2015 Aug;36(8):2340-7
pubmed: 25990306
J Alzheimers Dis. 2015;49(4):1123-34
pubmed: 26639957
J Alzheimers Dis. 2013;33 Suppl 1:S67-78
pubmed: 22531422
Neurobiol Aging. 2010 Aug;31(8):1284-303
pubmed: 20538372
Neurology. 2018 Jan 30;90(5):e388-e395
pubmed: 29321235
Ageing Res Rev. 2017 Jul;36:50-63
pubmed: 28315409
Brain. 2016 Aug;139(Pt 8):2249-60
pubmed: 27286736
J Alzheimers Dis. 2015;45(1):35-43
pubmed: 25547634
J Alzheimers Dis. 2006 Aug;9(3):253-60
pubmed: 16914835
Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):63-8
pubmed: 11234910
JAMA. 2017 Jun 13;317(22):2305-2316
pubmed: 28609533
J Alzheimers Dis. 2017;60(1):283-293
pubmed: 28800330
Int J Geriatr Psychiatry. 2012 Dec;27(12):1267-74
pubmed: 22383167
Alzheimer Dis Assoc Disord. 2016 Jan-Mar;30(1):1-7
pubmed: 26885819
J Prev Alzheimers Dis. 2017;4(2):109-115
pubmed: 29071250
JAMA Neurol. 2016 Sep 1;73(9):1070-7
pubmed: 27454922
Alzheimers Dement. 2014 Nov;10(6):684-9
pubmed: 24857233
Brain. 2017 May 1;140(5):1499-1512
pubmed: 28334939
Neurology. 2017 Nov 14;89(20):2031-2038
pubmed: 29046362
Acta Neuropathol. 2015 Feb;129(2):183-206
pubmed: 25604547
J Alzheimers Dis. 2011;26 Suppl 3:321-9
pubmed: 21971471
Sci Transl Med. 2016 Nov 2;8(363):363ra150
pubmed: 27807285
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):190-5
pubmed: 15592129
Brain. 2017 Mar 1;140(3):781-791
pubmed: 28122879
Alzheimers Dement. 2018 Apr;14(4):563-575
pubmed: 29653607
Ann Neurol. 2009 Aug;66(2):200-8
pubmed: 19743450
Ann Neurol. 2014 Aug;76(2):223-30
pubmed: 24852682
Brain. 2007 Sep;130(Pt 9):2320-6
pubmed: 17586559
Int J Geriatr Psychiatry. 2013 Jul;28(7):738-44
pubmed: 22911491
Neurology. 2016 Aug 2;87(5):539-47
pubmed: 27371494